journal article·2026-03Open access

Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination

Nicholas J. Tursi, Colby J. Agostino, Jinwei Huang, Toshitha Kannan, Niklas Laenger, Jennifer Londregan, Katlyn Lederer, Michaela Helble, Nicole Bedanova, Cory Livingston, Ebony N. Gary, Madison McCanna, Marta Tarquis Medina, Rumi Habib, Ignacio Rodriguez Relaño, Ivan Maillard, Ami Patel, David Allman, Andrew Kossenkov, Amelia Escolano, Daniel W. Kulp, David. B. Weiner

Advanced Science· Volume 13· Issue 14

Abstract

ABSTRACT Vaccine approaches capable of eliciting enhanced germinal center (GC) responses would result in improved protective humoral immunity against infectious diseases. Here, we investigate whether a cytokine can be scaffolded onto a self‐assembling nanoparticle immunogen to enhance antigen‐specific GC responses and B cell maturation. To test this approach, we design chimeric nanoparticles bearing eOD‐GT8, a germline‐targeting HIV immunogen, and IL‐21, a canonical GC cytokine. DNA delivery of these nanoparticle immunoadjuvant complexes (GT8‐IL‐21‐NICs) drives improved serum antibody titers and antigen‐specific GC B cell responses in mice. Transcriptomic analysis of eOD‐GT8‐specific GC B cells demonstrates upregulation of selection‐associated gene signatures with GT8‐IL‐21‐NIC immunization. In mice harboring human bnAb precursor heavy and light chain genes, immunization with the GT8‐IL‐21‐NIC leads to increased antibody diversity, clonal expansion, somatic hypermutation, and the acquisition of key antibody mutations. These results highlight IL‐21 as a promising genetic adjuvant and demonstrate that NICs may be a valuable tool to improve antigen‐specific GC responses and vaccine‐induced immunity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · HIV Research and Treatment · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Vaccine and Immunotherapy Centerthe Wistar Institute Philadelphia Pennsylvania USA

Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Biology Department Saint Joseph's University Philadelphia Pennsylvania USA

Division of Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York New York USA

Funding

National Science Foundation · INOVIO Pharmaceuticals

References (86)

Show source-provided references
1. 10.1146/annurev-immunol-120419-02240810.1146/annurev-immunol-120419-022408 ↗
2. 10.3389/fimmu.2021.66167810.3389/fimmu.2021.661678 ↗
3. 10.1016/j.immuni.2014.10.00410.1016/j.immuni.2014.10.004 ↗
4. 10.1016/j.immuni.2019.04.01110.1016/j.immuni.2019.04.011 ↗
5. 10.1038/ni.242810.1038/ni.2428 ↗
6. 10.3390/antib501000510.3390/antib5010005 ↗
7. 10.1084/jem.2009177710.1084/jem.20091777 ↗
8. 10.1016/j.immuni.2022.06.02010.1016/j.immuni.2022.06.020 ↗
9. 10.1016/j.immuni.2021.08.02810.1016/j.immuni.2021.08.028 ↗
10. 10.1016/j.immuni.2024.02.01810.1016/j.immuni.2024.02.018 ↗
11. 10.1126/science.aac589410.1126/science.aac5894 ↗
12. 10.1016/j.cell.2016.07.03010.1016/j.cell.2016.07.030 ↗
13. 10.1126/science.aax438010.1126/science.aax4380 ↗
14. 10.1126/sciimmunol.adk955010.1126/sciimmunol.adk9550 ↗
15. 10.1038/s41590-024-01833-w10.1038/s41590-024-01833-w ↗
16. 10.1126/science.add650210.1126/science.add6502 ↗
17. 10.1126/science.adr838210.1126/science.adr8382 ↗
18. 10.1126/science.aad919510.1126/science.aad9195 ↗
19. 10.1016/j.immuni.2022.09.00110.1016/j.immuni.2022.09.001 ↗
20. Deep Mining of the Human Antibody Repertoire Identifies Frequent and Immunogenetically Diverse CDRH3 Topologies Targetable by Vaccination
21. 10.1016/j.immuni.2020.08.00110.1016/j.immuni.2020.08.001 ↗
22. Antigen Avidity Drives the Durability of the Vaccine Immune Response
23. 10.1080/14760584.2019.157821610.1080/14760584.2019.1578216 ↗
24. 10.1021/cb600489g10.1021/cb600489g ↗
25. 10.1016/j.celrep.2016.04.07810.1016/j.celrep.2016.04.078 ↗
26. 10.1002/advs.20190280210.1002/advs.201902802 ↗
27. 10.1158/2326-6066.CIR-20-006110.1158/2326-6066.CIR-20-0061 ↗
28. 10.1016/j.celrep.2022.11031810.1016/j.celrep.2022.110318 ↗
29. 10.3389/fimmu.2023.107281010.3389/fimmu.2023.1072810 ↗
30. 10.1002/wnan.188010.1002/wnan.1880 ↗
31. 10.1016/j.vaccine.2020.03.04710.1016/j.vaccine.2020.03.047 ↗
32. 10.1016/j.xcrm.2022.10069310.1016/j.xcrm.2022.100693 ↗
33. 10.3389/fimmu.2023.113860910.3389/fimmu.2023.1138609 ↗
34. 10.1172/jci.insight.13707910.1172/jci.insight.137079 ↗
35. 10.1126/sciimmunol.ads132810.1126/sciimmunol.ads1328 ↗
36. 10.15252/embr.20225467710.15252/embr.202254677 ↗
37. 10.1038/ncomms1464710.1038/ncomms14647 ↗
38. 10.1038/ni110010.1038/ni1100 ↗
39. 10.1038/nri380410.1038/nri3804 ↗
40. 10.1016/j.immuni.2007.07.00910.1016/j.immuni.2007.07.009 ↗
41. 10.1016/j.celrep.2021.10996110.1016/j.celrep.2021.109961 ↗
42. R. P.Staupe L. A.Vella S.Manne et al. “Chronic viral infection promotes early germinal center exit of B cells and impaired antibody development” (2019) https://doi.org/10.1101/849844.10.1101/849844 ↗
43. 10.1016/j.cell.2010.10.03210.1016/j.cell.2010.10.032 ↗
44. 10.1182/blood-2012-03-41538010.1182/blood-2012-03-415380 ↗
45. 10.1093/intimm/dxad01710.1093/intimm/dxad017 ↗
46. 10.7554/eLife.5985010.7554/eLife.59850 ↗
47. 10.1038/ni135710.1038/ni1357 ↗
48. 10.3389/fimmu.2021.70584810.3389/fimmu.2021.705848 ↗
49. 10.1073/pnas.190125811610.1073/pnas.1901258116 ↗
50. 10.1038/s41577-020-00446-210.1038/s41577-020-00446-2 ↗
51. 10.1182/blood.201888013810.1182/blood.2018880138 ↗
52. 10.4049/jimmunol.150049710.4049/jimmunol.1500497 ↗
53. 10.1111/j.1600-065X.2009.00782.x10.1111/j.1600-065X.2009.00782.x ↗
54. 10.1016/j.celrep.2023.11251210.1016/j.celrep.2023.112512 ↗
55. 10.1016/j.immuni.2015.10.02110.1016/j.immuni.2015.10.021 ↗
56. 10.26508/lsa.20190050610.26508/lsa.201900506 ↗
57. 10.1084/jem.2016126310.1084/jem.20161263 ↗
58. 10.1084/jem.2020169910.1084/jem.20201699 ↗
59. 10.1126/science.119281910.1126/science.1192819 ↗
60. 10.1126/science.120753210.1126/science.1207532 ↗
61. 10.1126/science.120722710.1126/science.1207227 ↗
62. 10.1073/pnas.120898410910.1073/pnas.1208984109 ↗
63. 10.1073/pnas.221788312010.1073/pnas.2217883120 ↗
64. 10.1126/scitranslmed.adn022310.1126/scitranslmed.adn0223 ↗
65. 10.1038/s41586-019-1250-z10.1038/s41586-019-1250-z ↗
66. 10.1016/j.cell.2016.08.00510.1016/j.cell.2016.08.005 ↗
67. 10.1038/s41541-024-00971-410.1038/s41541-024-00971-4 ↗
68. 10.1016/j.cell.2025.07.00910.1016/j.cell.2025.07.009 ↗
69. 10.1038/s41590-022-01163-910.1038/s41590-022-01163-9 ↗
70. 10.1016/j.immuni.2020.11.00910.1016/j.immuni.2020.11.009 ↗
71. 10.1038/s41467-021-27477-010.1038/s41467-021-27477-0 ↗
72. 10.1038/s41467-022-33309-610.1038/s41467-022-33309-6 ↗
73. 10.1016/j.immuni.2008.06.00110.1016/j.immuni.2008.06.001 ↗
74. 10.4049/jimmunol.150146310.4049/jimmunol.1501463 ↗
75. 10.1016/j.it.2016.06.00110.1016/j.it.2016.06.001 ↗
76. 10.1016/j.immuni.2019.06.01310.1016/j.immuni.2019.06.013 ↗
77. 10.1038/ni.241810.1038/ni.2418 ↗
78. 10.1016/j.immuni.2005.09.01310.1016/j.immuni.2005.09.013 ↗
79. 10.1126/science.112570310.1126/science.1125703 ↗
80. 10.1016/j.xcrm.2025.10203510.1016/j.xcrm.2025.102035 ↗
81. 10.1038/s41586-021-03819-210.1038/s41586-021-03819-2 ↗
82. 10.1038/s41586-024-07487-w10.1038/s41586-024-07487-w ↗
83. 10.1038/s41592-022-01488-110.1038/s41592-022-01488-1 ↗
84. 10.1016/j.cell.2021.04.04810.1016/j.cell.2021.04.048 ↗
85. 10.1038/s41590-018-0276-y10.1038/s41590-018-0276-y ↗
86. 10.1186/s12864-018-4772-010.1186/s12864-018-4772-0 ↗